{
    "id": "5e039567-37bf-4ae6-aeab-82df1f8b8194",
    "indications": {
        "text": "fenofibrate tablets peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet : \u2022 reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . \u2022 treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . \u2022 severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . \u2022 renally impaired patients : initial dose 48 mg daily ( 2.4 ) . \u2022 geriatric patients : select dose basis renal function ( 2.5 ) . \u2022 may taken without regard meals ( 2.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fenofibrate tablets , usp available containing 145 mg fenofibrate , usp . 145 mg tablets white , film-coated , oval , unscored tablets debossed one side tablet fe4 side . available follows : ndc 68788-7932-3 bottles 30 tablets ndc 68788-7932-6 bottles 60 tablets ndc 68788-7932-9 bottles 90 tablets ndc 68788-7932-1 bottles 100 tablets dispense tight , light-resistant container defined usp using child-resistant closure .",
    "adverseReactions": "fenofibrate tablets contraindicated : \u2022patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . \u2022patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.2 ) ] . \u2022patients preexisting gallbladder disease [ ( 5.5 ) ] . \u2022nursing mothers [ ( 8.2 ) ] . \u2022patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "organization": "Preferred Pharmaceuticals Inc.",
    "name": "Fenofibrate",
    "effectiveTime": "20250509",
    "indications_original": "Fenofibrate tablets are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: \u2022 To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). \u2022 For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "\u2022 Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). \u2022 Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). \u2022 Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). \u2022 Geriatric patients: Select the dose on the basis of renal function ( 2.5 ). \u2022 May be taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate Tablets, USP are available containing 145 mg of fenofibrate, USP. \n                  The 145 mg tablets are white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and FE4 on the other side. They are available as follows:\n                  \n                     \n                        \u00a0NDC 68788-7932-3\tbottles of 30 tablets\n                     \n                        \u00a0NDC 68788-7932-6\tbottles of 60 tablets\n                     \n                        \u00a0NDC 68788-7932-9\tbottles of 90 tablets\n                     \n                        \u00a0NDC 68788-7932-1\tbottles of 100 tablets\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions_original": "Fenofibrate tablets are contraindicated in:\n                  \n                     \n                        \u2022patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].\n                     \n                     \n                        \u2022patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].\n                     \n                     \n                        \u2022patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].\n                     \n                        \u2022nursing mothers [see Use in Specific Populations (8.2)].\n                     \n                        \u2022patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)].",
    "drug": [
        {
            "name": "Fenofibrate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        }
    ]
}